Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F598 for prevention of experimental Neisseria gonorrhoeae infection
NCT03222401Phase 2Terminated
- Sponsor
- Alopexx, Inc.
- Start
- Nov 2017
- Primary completion
- Mar 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of F598 in gonorrhea, sponsored by Alopexx, Inc.. Started Nov 2017; status: terminated.
02
Drugs
F598
03
Conditions
gonorrhea
Beyond the preview
Go deeper on NCT03222401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03222401.